Dofequidar fumarate (MS-209) is an orally active quinoline compound that blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1). It has a highly potent reversing effect on multidrug-resistant tumor cells. Dofequidar fumarate competitively inhibits ABCB1/P-gp and ABCC1/MRP-1, blocking the efflux of chemotherapeutic agents, increasing drug concentration in cancer cells, and enhancing the chemotherapeutic effect. It is for research use only and not sold to patients.
- Orally active quinoline compound.
- Blocks P-glycoprotein (P-gp) and multidrug resistance-associated protein-1 (MDR-1).
- Highly potent reversing effect on multidrug-resistant tumor cells.
- Competitively inhibits ABCB1/P-gp and ABCC1/MRP-1.
- Blocks the efflux of chemotherapeutic agents.
- Increases drug concentration in cancer cells.
- Enhances the chemotherapeutic effect.